PPARβ/δ Agonism with GW501516 Increases Myotube PGC-1α Content and Reduces BCAA Media Content Independent of Changes in BCAA Catabolic Enzyme Expression

Caroline N. Rivera, Jason S. Hinkle, Rachel M. Watne, Trent C. Macgowan, Andrew J. Wommack, and Roger A. Vaughan

1Department of Exercise Science, High Point University, High Point, NC, USA
2Department of Chemistry, High Point University, High Point, NC, USA

Correspondence should be addressed to Roger A. Vaughan; rvaughan@highpoint.edu

Received 11 November 2022; Revised 1 May 2023; Accepted 17 May 2023; Published 6 June 2023

1. Introduction

Peroxisome proliferator-activated receptors (PPARs) are a nuclear receptor superfamily that include three isoforms that are differentially expressed in various tissues and regulate several aspects of cell energetics. In skeletal muscle, peroxisome proliferator-activated receptor delta (PPARβ/δ) is the predominant PPAR isoform that regulates mitochondrial content through the activation and upregulation of peroxisome proliferator-activated receptor gamma coactivator 1-alpha (PGC-1α) content [1]. PGC-1α acts as a transcriptional cofactor regulating the expression of nuclear respiratory factors (NRF1/2) [2–4] and mitochondrial transcription factor A (TFAM) [3, 5, 6], which together coordinate mitochondrial biogenesis [7]. Consistent with these observations, PPARβ/δ-deficient skeletal muscle displays reduced genes associated with fatty acid uptake and oxidation, as well as mitochondrial respiratory components, which may result from reduced regulators of mitochondrial biogenesis including PGC-1α and TFAM [8].

In addition to insulin resistance and elevated circulating glucose, reduced PGC-1α expression in metabolically
meaningful tissues also occurs in the diabetic phenotype [9]. Moreover, like many circulating metabolites that are elevated during metabolic disease (such as glucose and lipids), amino acids, specifically the branched-chain amino acids (BCAA), have been consistently correlated with severity of insulin resistance [10–13]. One possible mechanism linking insulin resistance to increased circulating BCAA is that metabolically diseased populations may experience diminished BCAA catabolic capacity [14]. Thus, it is conceivable BCAA may accumulate in the blood of those with diabetes due to reduced BCAA metabolism. Interestingly, the BCAA degradation enzymes, branched-chain alpha-keto acid dehydrogenase (BCKDH) and branched-chain aminotransferase (BCAT) [15], are controlled by both the PPARs and PGC-1α [16–19]. In line with these observations, Lian et al. showed activation of myotube 5′-AMP-activated protein kinase (AMPK), a master regulator of energetics which activates PGC-1α [20], appears to increase BCAA catabolic enzyme expression and/or activity [21]. Importantly, however, activation of BCAA catabolism via AMPK activators, such as AICAR during cell culture experiments, might be dependent on concentration and glucose availability [22], and may reduce BCAA catabolism despite an upregulation of BCAA catabolic enzymes, which may accompany metabolic stress as seen with atrophy [23, 24]. Collectively, these observations agree with others demonstrating exercise (another activator of PPARβ/δ, AMPK, and PGC-1α) increases BCAA metabolism [15]. Taken together, it is conceivable the activation of PPARβ/δ, which works synergistically with AMPK and PGC-1α, represents a potential method of improving mitochondrial function (and BCAA metabolism), which is often suppressed during insulin resistance.

Several past reports have shown the selective PPARβ/δ agonist, GW501516 (GW), can activate PPARβ/δ and PGC-1α leading to improved mitochondrial function. For example, L6 myotubes treated with GW exhibited increased palmitate oxidation and PGC-1α expression, as well as consistently elevated mRNA expression of indicators of lipid oxidation [1]. The effect of GW on palmitate oxidation was also observed in C57BL/6j mice, as were elevations in PGC-1α expression, lipid oxidation enzymes, and uncoupling protein mRNA expression [1]. Not surprisingly, GW-treated mice displayed increased skeletal mitochondrial content in both Chow- and high-fat-fed mice. Thus, it was concluded that PPARβ/δ activation upregulates both PGC-1α expression and mitochondrial biogenesis both in vitro and in vivo [1]. Other reports have found similar results. For example, treatment with GW and BMS649 (a selective retinoid X receptor (RXR) agonist) induced PGC-1α expression in C2C12 myocytes [8]. Another report showed C2C12 myoblasts treated for 24 hours with 1 μM GW displayed increased PGC-1α promoter activity and expression [25]. Similarly, C2C12 myotubes treated with GW for 24 hours displayed increased PGC-1α and carnitine palmitoyl transferase 1 b (Cpt1b) mRNA, which was PPARβ/δ-dependent (not induced by PPARα activation). The same report showed PGC-1α also controlled PPARβ/δ expression. Moreover, L6 myotubes treated with GW for 24 hours showed increased palmitate oxidation, CPT1b, and cytochrome c oxidase expression [26]. GW at 5 μM has been shown to increase oleic acid oxidation and Cpt1 mRNA expression [27]. And in mice with myocardial infarction, those treated with GW also exhibited increased oleic acid oxidation and enhanced Cpt1 mRNA expression, but not PGC-1α expression, which corresponded to increased running duration and distance [27]. Another report also demonstrated myotubes treated with GW displayed increased Cpt1 mRNA expression; however, GW-treated cells displayed unaltered mitochondrial respiration but increased proton leak [28]. Interestingly, primary myotubes exposed to GW for 6 hours displayed unaltered Ppargc1a and reduced Ppard mRNA expression; however, GW-treated cells also displayed enhanced glucose uptake [29]. Together, much of the available data suggest PPARβ/δ agonism via GW efficiently and reliably activates PGC-1α expression (as well as related downstream targets). However, to our knowledge, no report has also simultaneously investigated the effects of PPARβ/δ agonism using GW on metabolism as well as regulators of BCAA catabolism in muscle. Because PGC-1α has been shown to regulate BCAA catabolic enzymes [16, 19, 30] (which is reduced in those with diabetes [9]), we sought to determine if PPARβ/δ agonism via GW would alter cell metabolism as well as indicators of BCAA catabolism in a model of skeletal muscle.

2. Materials and Methods

2.1. Cell Culture. C2C12 mouse myoblasts from ATCC (Manassas, VA) were cultured in Dulbecco’s Modified Eagle’s Medium (DMEM) containing 4500 mg/L glucose and supplemented with 20% heat-inactivated fetal bovine serum (FBS), 100 μg/mL penicillin, and 100 μg/mL streptomycin in a humidified 5% CO2 atmosphere at 37°C. Cells were grown to confluence with growth media changed every 2–3 days (using cell passages <15 for all experiments). Differentiation was accomplished by replacing growth media with DMEM supplemented with 2% horse serum, 100 μg/mL penicillin, and 100 μg/mL streptomycin for 6–8 days. Stock GW501516 (GW) from Enzo Life Sciences (Farmingdale, NY) was dissolved in dimethylsulfoxide (DMSO) to a concentration of 1 mM. Cells were then treated with either differentiation media containing equal volume DMSO (0.1% vol/vol), which served as the control condition, or GW at 1 μM (also containing 0.1% vol/vol DMSO) for up to 24 hours, which has been shown to be sufficient for increasing PPARβ/δ activity by previous observations [25, 26, 28, 31]. Table 1 summarizes GW treatment doses and durations from similar reports. To discern the potential mechanistic involvement of PPARβ/δ, we repeated experiments with and without GSK3787 (GSK), a selective PPARβ/δ antagonist [32, 33], at 10 μM (also using 0.1% vol/vol DMSO). Therefore, during inhibition experiments with GSK, DMSO volume was increased and normalized to 0.2% vol/vol for all groups. To further investigate the effects of GW on BCAA metabolism during insulin resistance, we also included insulin resistant groups during select experiments. Insulin resistance was induced by the addition of insulin.
100 nM for the final 3 days of differentiation [34–38], which significantly reduces insulin-mediated insulin receptor activation, insulin-mediated insulin receptor substrate 1 (IRS1) activation, insulin-mediated phosphatidylinositol-3 kinase (PI3K) activation, and insulin-mediated glucose uptake without altering cell differentiation status [37, 38]. In addition to these targets, Akt is a target of insulin downstream of IRS1 and PI3K, which is regarded as a central node in the proximal insulin signaling cascade [39]. This model of insulin resistance has been shown to dose-dependently reduce Akt activation following insulin stimulation [36, 40], and was therefore used in the current report. Additionally, we have previously shown that this model of insulin resistance leads to the extracellular accumulation of BCAA within media following a single day recovery with stock media (composition available at the following product link: 12-614-Lonza Bioscience) [41]. Thus, cells were treated with and without both GW and/or GSK in stock media following the induction of insulin resistance or not.

2.2. Cell Viability and Nuclei Content. Following treatment as described above, media was replaced with media supplemented with Water-Soluble Tetrazolium 1 (WST-1) substrate. Cells/media supernatant were immediately measured for absorbance at 450 nm temporally for 90 minutes. Cell viability did not differ between any groups (Figures 1(a) and 1(b)). In separate experiments, media was collected following treatment as described above, and cells were fixed using media supplemented with 3.7% formaldehyde at 37°C with a 5% CO₂ atmosphere. The fixing agent was then removed, and cells were stained with 4′,6-diamidino-2-phenylindole (DAPI) at 0.5 μM in phosphate buffered saline (PBS), incubated in the dark at room temperature for 10 minutes, and fluorescence was measured at 360/460 nm, which did not significantly differ between groups (Figure 1(c)). Both experiments were performed using two independent experiments each comprised of four replicates per group for n = 6 in the final analyses. Measurements were performed in triplicate, and the average was used for both outcomes.

2.3. Quantitative Real-Time Polymerase Chain Reaction. To investigate the effect of GW on protein expression of related metabolic targets, cells were differentiated and treated as described above. Total mRNA was extracted using the Trizol method and quantified (via NanoDrop from Thermo Fisher, Wilmington, DE), and cDNA was synthesized using the iScript cDNA Synthesis Kit from Bio-Rad (Hercules, CA) according to manufacturer’s instructions. Polymerase chain reaction (PCR) primers were synthesized by Integrated

### Table 1: Summary of experimental model, treatment conditions, and related findings to present report.

<table>
<thead>
<tr>
<th>Model</th>
<th>Dose of GW501516</th>
<th>Duration</th>
<th>Effect</th>
<th>Reference</th>
</tr>
</thead>
<tbody>
<tr>
<td>Myotubes</td>
<td>10 nM</td>
<td>16 hours</td>
<td>↑ Glucose uptake</td>
<td>Kramer et al. [29]</td>
</tr>
<tr>
<td></td>
<td>100 nM</td>
<td>24 hours</td>
<td>↑ Cpt1, Pdk4, Ucp3 mRNA</td>
<td>Kleiner et al. [42]</td>
</tr>
<tr>
<td></td>
<td>1 μM</td>
<td>24 hours</td>
<td>↑ Pdk4 mRNA expression</td>
<td>Aoki et al. [43]</td>
</tr>
<tr>
<td></td>
<td>1 μM</td>
<td>24 hours</td>
<td>↑ Cpt1, Pdk4, Ucp3 mRNA and →mitochondrial function</td>
<td>Tumova et al. [28]</td>
</tr>
<tr>
<td></td>
<td>1 μM</td>
<td>24 hours</td>
<td>↑ PPAR and PGC-1α promoter activity and Pparα1a and Cpt1 mRNA expression</td>
<td>Hondares et al. [26]</td>
</tr>
<tr>
<td></td>
<td>1 μM</td>
<td>24 hours</td>
<td>↑ PPAR and PGC-1α promoter activity and Ucp2 mRNA expression</td>
<td>Miura et al. [25]</td>
</tr>
<tr>
<td></td>
<td>1 μM</td>
<td>24 hours</td>
<td>↑ PPAR and PGC-1α promoter activity and Ucp1, Ucp2, Ucp3 mRNA expression</td>
<td>Dressel et al. [44]</td>
</tr>
<tr>
<td></td>
<td>1 μM</td>
<td>24 hours</td>
<td>↑ PPAR and PGC-1α promoter activity</td>
<td>Schuler et al. [8]</td>
</tr>
<tr>
<td></td>
<td>1 μM</td>
<td>24 hours</td>
<td>↑ Palmitate oxidation and Cpt1 mRNA expression</td>
<td>Coll et al. [45]</td>
</tr>
<tr>
<td></td>
<td>1 μM</td>
<td>24 hours</td>
<td>↑ PPAR reporter activity</td>
<td>Remels et al. [31]</td>
</tr>
<tr>
<td></td>
<td>1 μM</td>
<td>24 hours</td>
<td>↑ Or rescued Cpt1 mRNA expression/rescued palmitate oxidation (TNFα suppressed)</td>
<td>Zizola et al. [27]</td>
</tr>
<tr>
<td>L6</td>
<td>1 μM + BMS691 at 10 μM</td>
<td>16 hours</td>
<td>↑ Pparα1a mRNA</td>
<td>Aguilar-Recarte et al. [46]</td>
</tr>
<tr>
<td>L6</td>
<td>1 μM + PAL at 500 μM</td>
<td>16 hours</td>
<td>↑ pAMPK, PDK4, and CPT1 protein expression and rescued palmitate oxidation</td>
<td>Tanaka et al. [1]</td>
</tr>
<tr>
<td>C2C12</td>
<td>1 μM</td>
<td>24 hours</td>
<td>↑ Or rescued Cpt1 mRNA expression/rescued palmitate oxidation (TNFα suppressed)</td>
<td>Dressel et al. [46]</td>
</tr>
<tr>
<td>Myotubes</td>
<td>5 μM</td>
<td>16 hours</td>
<td>↑ Acc1, Acadm, and Acox mRNA expression and pAMPK protein expression</td>
<td>Schuler et al. [8]</td>
</tr>
<tr>
<td></td>
<td>10 μM</td>
<td>24 hours</td>
<td>↑ Cpt-1b, Acadm, and Acox mRNA expression and pAMPK protein expression</td>
<td>Coll et al. [45]</td>
</tr>
<tr>
<td></td>
<td>30, 100, and 300 nM (L6 myotubes)</td>
<td>24 hours</td>
<td>↑ Pparα1a, Ucp2, Ucp3, and Cpt1 mRNA expression and palmitate oxidation</td>
<td>Dimopoulos et al. [48]</td>
</tr>
<tr>
<td></td>
<td>100 nM (L6 myotubes)</td>
<td>5 days</td>
<td>↑ UCP3 and ↓GLUT4 protein expression</td>
<td>Hondares et al. [26]</td>
</tr>
<tr>
<td>L6</td>
<td>1 μM (L6 myotubes)</td>
<td>24 hours</td>
<td>↑ PGC-1α and CPT1 with → PPARα protein expression and ↑ palmitate oxidation</td>
<td>Dressel et al. [46]</td>
</tr>
<tr>
<td></td>
<td>1 μM (L6 myotubes)</td>
<td>24 hours</td>
<td>↑ Palmite oxidation and Cpt1 mRNA expression</td>
<td>Schuler et al. [8]</td>
</tr>
</tbody>
</table>

*Indicates effects were enhanced by concurrent RXR agonism. Abbreviations: Cpt1: carnitine palmitoyl transferase 1; Glut4: glucose transporter 4; Pparα1a: peroxisome proliferator-activated receptor gamma coactivator 1-alpha; Pparα: peroxisome proliferator-activated receptor delta; Pdk4: pyruvate dehydrogenase kinase 4; Ucp: uncoupling protein.
DNA Technologies (Coralville, IA) (Table 2). Amplification of target genes was normalized to the housekeeping gene, TATA binding protein (Tbp), which did not significantly differ between groups (Figure 2). Quantitative real-time polymerase chain reactions (qRT-PCR) were performed using the CFX Connect System from Bio-Rad (Hercules, CA). SYBR Green-based PCR was performed using final primer concentrations at 3.75 μM in a total volume of 10 μl per well. The following cycling parameters were used: 95°C for 3 minutes followed by 40 cycles of 95°C for 15 seconds, and 60°C for 30 seconds. qRT-PCR was performed using n = 3 per treatment condition from two independent experiments with n = 6 for the final analysis. Relative quantification was determined via ΔΔCt method.

2.4. Immunoblotting. To investigate the effect of GW on protein expression of related metabolic targets, cells were differentiated and treated as described above. Whole cell lysates were then prepared by harvesting the cells on ice in Radioimmunoprecipitation Assay (RIPA) buffer supplemented with protease inhibitor mix (0.1%), followed by incubation on ice for 60 minutes. Insoluble material was removed, and protein concentrations were determined by Bradford assay. Total protein (50 μg per sample) was size-separated by 10% sodium dodecyl sulfate–polyacrylamide gel electrophoresis (SDS-PAGE) and electro-transferred to polyvinylidene difluoride (PVDF) membranes. After blocking in tris-buffered saline with tween (TBST) with 5% non-fat milk powder for 1 hour, membranes were probed at 4°C overnight with antibodies, as described in Table 3, at a dilution of 1:1000 in TBST-5% non-fat milk powder (with the exception of large amino acid transporter 1 [LAT1] for which a dilution of 1:500 was used). Relative signal intensities were normalized to β-actin (or total target for phosphorylation of BCKDHa) and quantified using Image Lab from Bio-Rad (Hercules, CA). Bound antibodies were detected by horseradish peroxidase-conjugated secondary antibodies from AbCam (Cambridge, MA) at a dilution of 1:5000 in

Figure 1: Cell viability. (a and b) Effect of GW501516 (GW) at 1 μM for 24 hours both with and without GSK3787 at 10 μM both with and without insulin resistance presented as (a) WST-1 assay time trial or (b) final relative measurement at 90 minutes. (c) Relative nuclei content from cells treated as described in "a" with representative images presented at right. Notes: Data were analyzed using one-way ANOVA with Bonferroni’s correction for multiple comparisons. Measurements were performed using n = 3 individual replicates per treatment condition and were repeated across two independent experiments with n = 6 per group in the final analyses using the average of three measurements per experiment. Representative images from DAPI staining were taken using the 20× objective with red line indicating 150 μm.
TBST-5% non-fat milk powder for 1 hour at room temperature while shaking. Protein signal intensities were determined by chemiluminescence using the Clarity Western ECL substrate kit from Bio-Rad (Hercules, CA) and imaged using the ChemiDoc Touch from Bio-Rad (Hercules, CA). Blots were performed using three replicates per condition.

**Figure 2:** Effect of GW501516 on Tbp Ct values from qRT-PCR experiments. Notes: Time course gene expression was analyzed using one-way ANOVA with Bonferroni’s correction for multiple comparisons with no significant pair-wise comparisons identified. Tata binding protein (Tbp) values were measured using three replicates per group across two independent experiments with n = 6 for the final analysis.

### Table 2: Summary of qRT-PCR primers from Integrated DNA Technologies (Coralville, IA).

<table>
<thead>
<tr>
<th>Gene abbreviation</th>
<th>Forward sequence</th>
<th>Reverse sequence</th>
</tr>
</thead>
<tbody>
<tr>
<td>Atp5b</td>
<td>5'-AGGCCCTTTGGCCAAGCTT-3'</td>
<td>5'-TTCTCCTATAGTGACAGGTACA-3'</td>
</tr>
<tr>
<td>Bcat2</td>
<td>5'-CGGACCTCTTCTCAGAAGGTTGAGAGA-3'</td>
<td>5'-CACTAGTCCCGGGGTTCAGCTTG-3'</td>
</tr>
<tr>
<td>Bckdha</td>
<td>5'-CCAGGGGTGGTGGAGGATGAG-3'</td>
<td>5'-GGGCTTCCATGACCTTTTCG-3'</td>
</tr>
<tr>
<td>Cebp</td>
<td>5'-GTGGTGACGCTCTATGCTAACA-3'</td>
<td>5'-GGCGTATTGTAAGAGTCTCAGTTG-3'</td>
</tr>
<tr>
<td>Cox5a</td>
<td>5'-AACCTGCTGCTCTACCTC-3'</td>
<td>5'-ACCTGCTAGAGGATGAGG-3'</td>
</tr>
<tr>
<td>Cs</td>
<td>5'-TGGAGGCAAGGAGGTGTGAGA-3'</td>
<td>5'-GACACCCTGGATGATCAGA-3'</td>
</tr>
<tr>
<td>Fat (CD36)</td>
<td>5'-TAGTAGAAGCGGCCAGCTGTA-3'</td>
<td>5'-CAGTTCCGATCAGCCCAT-3'</td>
</tr>
<tr>
<td>Slc2a4 (Glut4)</td>
<td>5'-GATGAGAAAGGAAATGGAGAGA-3'</td>
<td>5'-GACACCCTGGATGATCAGA-3'</td>
</tr>
<tr>
<td>Hibadh</td>
<td>5'-GCAGCGGTGTTCTAGGTCT-3'</td>
<td>5'-ACACGTCTAGAGGATGAGG-3'</td>
</tr>
<tr>
<td>Ldhb</td>
<td>5'-GGCTGTGACGCTCAGTATCT-3'</td>
<td>5'-GGCGCTAAAGTCTCATTAT-3'</td>
</tr>
<tr>
<td>Nrf1</td>
<td>5'-ACCTCCTGCTACGACTAT-3'</td>
<td>5'-GACACCTCCTCAGACCTAAC-3'</td>
</tr>
<tr>
<td>Pdh</td>
<td>5'-GAAGGCCCTGCATTCAACTCT-3'</td>
<td>5'-ATAGGGACATCAGCACCAGTA-3'</td>
</tr>
<tr>
<td>Ppargc1a</td>
<td>5'-GGACATCCCGGCAAGACATCAG-3'</td>
<td>5'-AGAGAGGAGAGAGAGAGA-3'</td>
</tr>
<tr>
<td>Ppara</td>
<td>5'-CTCGCGTGTGATAAACG-3'</td>
<td>5'-CGATGCTGCTTCTG-3'</td>
</tr>
<tr>
<td>Ppargd</td>
<td>5'-GCTCCGCGCTCTCAGTAC-3'</td>
<td>5'-AGATCGTGACCTTC-3'</td>
</tr>
<tr>
<td>Pparg</td>
<td>5'-TCGCCTGCTGGAGTCACCT-3'</td>
<td>5'-GGAGTTGTTGCGGCAAAT-3'</td>
</tr>
<tr>
<td>Scd1</td>
<td>5'-CATCGCCGTCTCTACCTT-3'</td>
<td>5'-GAACCTCCTCCAGACCTAAC-3'</td>
</tr>
<tr>
<td>Srebpl</td>
<td>5'-ATGCAGAGGGAATGGGAG-3'</td>
<td>5'-AGATCCGAGGTTGAGG-3'</td>
</tr>
<tr>
<td>Tbp</td>
<td>5'-GGGATTCCAGGAAGACCACAATA-3'</td>
<td>5'-CCTCACAACGTGATCAGA-3'</td>
</tr>
<tr>
<td>Tfam</td>
<td>5'-GAAGAGGAATGGGAAAGGTAGA-G-3'</td>
<td>5'-ACAGGAGCATGGAAGGACAT-3'</td>
</tr>
</tbody>
</table>

**Abbreviations:** Atp5b: ATP synthase F1; Bcat2: branched-chain aminotransferase 2; Bckdha: branched-chain alpha-keto acid dehydrogenase; Cebp: CCAAT-enhancer-binding protein alpha; Cox5a: cytochrome C oxidase Subunit 5A; Cs: citrate synthase; Fat or CD36: fatty acid translocase; Slc2a4 or Glut4: glucose transporter 4; Hibadh: 3-hydroxyisobutyrate dehydrogenase; Ldhb: lactate dehydrogenase b; Nrf1: nuclear respiratory factor 1; Pdh: pyruvate dehydrogenase; Ppargc1a: peroxisome proliferator-activated receptor gamma coactivator 1-alpha; Ppara: peroxisome proliferator-activated receptor alpha; Pparg: peroxisome proliferator-activated receptor delta; Srebpl: sterol regulatory element-binding protein; Tbp: TATA box binding protein; and Tfam: mitochondrial transcription factor A.
ATP synthase) at a each well was infused with oligomycin (an inhibitor of metabolism, respectively. Following basal measurements, indicators of basal oxidative metabolism and glycolytic

### Table 3: Summary of primary antibodies used for western blot experiments.

<table>
<thead>
<tr>
<th>Protein target</th>
<th>Type</th>
<th>Dilution</th>
<th>Company</th>
<th>Item</th>
<th>Approx. Mol Wt.</th>
<th>Product link</th>
</tr>
</thead>
<tbody>
<tr>
<td>ACAD9</td>
<td>RP</td>
<td>1 : 1000</td>
<td>SC Biotechnology</td>
<td>sc-135148</td>
<td>68kd</td>
<td>Datasheet</td>
</tr>
<tr>
<td>pAkt (Ser 473)</td>
<td>RP</td>
<td>1 : 1000</td>
<td>SC Biotechnology</td>
<td>sc-7985-R</td>
<td>62kd</td>
<td>p-Akt1/2/3 (Ser 473)</td>
</tr>
<tr>
<td>Akt</td>
<td>RP</td>
<td>1 : 1000</td>
<td>Cell Signaling</td>
<td>9272</td>
<td>62kd</td>
<td>Akt Antibody#9272</td>
</tr>
<tr>
<td>β-Actin</td>
<td>RP</td>
<td>1 : 1000</td>
<td>SC Biotechnology</td>
<td>sc-130656</td>
<td>43kd</td>
<td>Datasheet</td>
</tr>
<tr>
<td>BCAT2</td>
<td>RP</td>
<td>1 : 1000</td>
<td>Bios</td>
<td>BS-6589R</td>
<td>44kd</td>
<td>Datasheet</td>
</tr>
<tr>
<td>BCKDHa</td>
<td>RP</td>
<td>1 : 1000</td>
<td>ProSci</td>
<td>31-325</td>
<td>50kd</td>
<td>BCKDHA Antibody</td>
</tr>
<tr>
<td>pBCKDHa (Ser 293)</td>
<td>RP</td>
<td>1 : 1000</td>
<td>AbCam</td>
<td>ab200577</td>
<td>50kd</td>
<td>Phospho BCKDHA (S293)</td>
</tr>
<tr>
<td>CPT1b</td>
<td>RP</td>
<td>1 : 1000</td>
<td>SC Biotechnology</td>
<td>sc-20670</td>
<td>75kd</td>
<td>Datasheet</td>
</tr>
<tr>
<td>CS</td>
<td>MM</td>
<td>1 : 1000</td>
<td>SC Biotechnology</td>
<td>sc-390693</td>
<td>52kd</td>
<td>sc-390693</td>
</tr>
<tr>
<td>ERRα</td>
<td>RP</td>
<td>1 : 1000</td>
<td>SC Biotechnology</td>
<td>sc-66882</td>
<td>53kd</td>
<td>Datasheet</td>
</tr>
<tr>
<td>LAT1</td>
<td>RP</td>
<td>1 : 500</td>
<td>NOVUS Biological</td>
<td>NBP3-09988</td>
<td>47kd</td>
<td>Datasheet</td>
</tr>
<tr>
<td>NRF1</td>
<td>RP</td>
<td>1 : 1000</td>
<td>SC Biotechnology</td>
<td>sc-33771</td>
<td>68kd</td>
<td>Datasheet</td>
</tr>
<tr>
<td>PGC-1α</td>
<td>RP</td>
<td>1 : 1000</td>
<td>SC Biotechnology</td>
<td>sc-13067</td>
<td>90kd</td>
<td>PGC-1α (H-300)</td>
</tr>
<tr>
<td>PPARβ/δ</td>
<td>RP</td>
<td>1 : 1000</td>
<td>SC Biotechnology</td>
<td>sc-7197</td>
<td>52kd</td>
<td>Datasheet</td>
</tr>
<tr>
<td>PPARγ</td>
<td>RP</td>
<td>1 : 1000</td>
<td>SC Biotechnology</td>
<td>sc-7196</td>
<td>52kd</td>
<td>Datasheet</td>
</tr>
<tr>
<td>SREBP1</td>
<td>RP</td>
<td>1 : 1000</td>
<td>SC Biotechnology</td>
<td>sc-366</td>
<td>68kd</td>
<td>Datasheet</td>
</tr>
<tr>
<td>TFAM</td>
<td>RP</td>
<td>1 : 1000</td>
<td>SC Biotechnology</td>
<td>sc-28200</td>
<td>25kd</td>
<td>Datasheet</td>
</tr>
<tr>
<td>UCP1/2/3</td>
<td>RP</td>
<td>1 : 1000</td>
<td>SC Biotechnology</td>
<td>sc-28766</td>
<td>33kd</td>
<td>Datasheet</td>
</tr>
</tbody>
</table>

Abbreviations: ACAD9: Acyl-coA dehydrogenase 9; BCAT2: branched-chain aminotransferase 2; BCKDHE1α: branched-chain alpha-keto acid dehydrogenase E1α; CPT1b: carnitine palmitoyl transferase; CS: citrate synthase; ERRα: estrogen-related receptor alpha; LAT1: large amino acid transporter 1; MM: mouse monoclonal; NRF1: nuclear respiratory factor 1; PGC-1α: peroxisome proliferator-activated receptor gamma coactivator 1-α; PPARβ/δ: peroxisome proliferator-activated receptor beta/delta; PPARγ: peroxisome proliferator-activated receptor gamma; SREBP1: sterol regulatory element-binding proteins; RP: rabbit polyclonal; TFAM: mitochondrial transcription factor A; and UCP: uncoupling protein 1/2/3. Notes: Target molecular weight was based on product datasheet. Molecular weights for all targets were verified against sizes suggested by product brochures.

performed across two independent experiments with \( n = 6 \) for the final analysis. Each target was also measured in duplicate for each experiment, and the average was used in the final analyses. Molecular weights for all targets were verified against sizes suggested by product brochures (Table 3).

### 2.5. Seahorse Metabolic Assays.** For MitoStress assays cells were seeded into Seahorse XFe96 culture plates and differentiated for 6 days once reaching confluence. Following treatment with GW for 24 hours, media was replaced with XF Assay Media obtained from Agilent Technologies (Santa Clara, CA) containing glucose at 25 mM, pyruvate at 1 mM, and glutamine at 2 mM. Following incubation, baseline measurements of oxygen consumption rate (OCR) and extracellular acidification rate (ECAR) were recorded as indicators of non-mitochondrial metabolism and glycolytic metabolism, respectively. Following basal measurements, each well was infused with oligomycin (an inhibitor of ATP synthase) at a final concentration of 2 \( \mu \text{M} \) to induce maximal glycolytic metabolism. Cells were then exposed to carbonyl cyanide p-[trifluoromethoxy]-phenyl-hydrazone (FCCP) at 2 \( \mu \text{M} \) to uncouple electron transport and induce peak OCR. Maximal respiration measurements were followed by the injection of rotenone at 1 \( \mu \text{M} \) to reveal non-mitochondrial respiration. Basal and peak oxidative metabolism were calculated by subtracting non-mitochondrial OCR from each respective well. The Seahorse XFe96 Analyzer was run using a 6-minute cyclic protocol command (mix for 3 minutes and measure for 3 minutes). MitoStress assays included \( n = 23 \) per group repeated with two independent experiments for \( n = 46 \) per group for the final analysis. No wells presented with negative OCR values or lack of response to injection.

### 2.6. Nuclear, Mitochondrial, and Nile Red Staining.** Immediately following the Seahorse metabolic assay as described above, cells were fixed using 3.7% formaldehyde at 37°C with a 5% \( \text{CO}_2 \) atmosphere. The fixing agent was then removed, and cells were stained with DAPI at 0.5 \( \mu \text{M} \) in PBS, incubated in the dark at room temperature for 10 minutes, and fluorescence was measured at 360/460 nm, which did not significantly differ between groups (Figure 3). Next, to assess mitochondrial content, cells were stained with 100 \( \mu \text{M} \) nonyl acridine orange (NAO) (Fremont, CA) in PBS and incubated in the dark at room temperature for 10 minutes. Fluorescence was then measured using 485/525 nm excitation/emission and quantified in triplicate and the average (less background). Lastly, to measure lipid content, cells were fixed as described above and stained with Nile Red in PBS at 10 \( \mu \text{M} \) Nile Red (1% DMSO vol/vol) and incubated at room temperature in the dark for approximately 5 minutes. Fluorescence was measured using 530/645 nm excitation/emission and quantified in duplicate, and the average (less background) was used in analysis. Each fluorescent measurement was performed using \( n = 23 \) per group repeated with two independent experiments with \( n = 46 \) per group for the final analyses, with each measurement performed in
2.7. BCAA Media Content and Liquid Chromatography-Mass Spectrometry. Using a modified protocol similar to previous measurements of BCAA in human plasma [49], media BCAA content was assessed. For experiments with both insulin resistance and GSK3787 inhibition, cells were fixed immediately following media collection using 3.7% formaldehyde at 37°C. Following formaldehyde fixation, cells were permeabilized, and cell nuclei were stained with DAPI at 4°C. DAPI-stained cells were imaged at 20× using the Motic AE31E inverted microscope and Moticam Pro 252B (Causeway Bay, Hong Kong).

2.8. Statistical Analyses. Data are presented as dot plots or group mean ± SE. Protein expression from 24-hour experiments was analyzed using student’s t-test. Time course gene expression was analyzed using one-way ANOVA with Dunnett’s correction for multiple comparisons. Metabolism time trials were analyzed via two-way ANOVA with Bonferroni’s correction for multiple comparisons. Mitochondrial metabolism, mitochondrial and lipid content, as well as BCAA media content for experiments only including control and GW groups were analyzed using student’s t-test. Total cell metabolism was analyzed using a one-way MANOVA using Wilks’ Lambda, with treatment as the independent variable and mitochondrial respiration and glycolytic metabolism as the two dependent variables. BCAA media content, nuclei content, and viability for experiments with and without PPARβ/δ agonist both with and without insulin resistance were analyzed initially with factorial-ANOVA followed by pair-wise comparisons with Bonferroni’s correction. Values of p ≤ 0.05 were used to identify significant differences between groups.

3. Results

3.1. GW Increases Cell Metabolism, Mitochondrial Content, and PGC-1α Expression. We began our investigation by measuring the effect of GW-mediated PPARβ/δ agonism on mitochondrial metabolism (Figures 5(a), 5(b), and 5(c)) and content (Figure 5(d)) following 24-hour treatment. Both basal and peak mitochondrial respiration were significantly increased in GW-treated cells (Figures 5(a), 5(b), and 5(c)). This led us to assess mitochondrial content, which was also
increased following GW treatment (Figure 5(d)). Interestingly, after normalizing mitochondrial function to mitochondrial content, changes in mitochondrial function were returned to values statistically similar to control cells, suggesting improvements in mitochondrial function were proportional (and perhaps resultant from) increases in mitochondrial content (Figure 5(e)). And not surprisingly, when analyzed via linear regression, mitochondrial staining closely predicted peak mitochondrial function (Figure 5(f)). We also assessed the effect of GW on other characteristics of mitochondrial metabolism and observed unchanged proton leak and ATP production following treatment regardless of normalization to nuclei content (Figures 5(g) and 5(h)). Conversely, spare capacity and non-mitochondrial respiration were significantly increased in GW-treated cells both without and with controlling for nuclei content (Figures 5(g) and 5(h), respectively). Next, we investigated gene expression of several regulators of mitochondrial biogenesis. Expressions of Cox5a and Atp5b were significantly reduced by GW at 3, 6, and 24 hours, and Atp5b was significantly reduced at 3 and 24 hours;
Figure 5: Continued.
Figure 5: Effect of GW501516 on mitochondrial metabolism and content. (a) Time trial of mitochondrial metabolism following treatment with and without GW501516 (GW) at 1 μM for 24 hours. (b and c) Basal and peak mitochondrial metabolism following treatment described in “a” presented as (b) raw values or (c) normalized to nuclei content, which did not differ between groups (see Figure 3). (d) Effect of GW at 1 μM for 24 hours on mitochondrial proton leak (uncoupling), ATP production, mitochondrial spare respiratory capacity, and non-mitochondrial (non-mt) respiration, both without and with normalization to DAPI, respectively. Notes: * indicates p ≤ 0.05 between groups. States of mitochondrial metabolism, as well as mitochondrial staining, were analyzed using student’s t-test. States of mitochondrial metabolism were calculated by subtracting non-mitochondrial respiration from basal and FCCP-induced peak mitochondrial oxygen consumption (OCR). Time course of mitochondrial function was analyzed using two-way ANOVA with Bonferroni s correction for multiple comparisons. Metabolic analyses were performed using n = 23 individual replicates per treatment condition and repeated across two independent experiments with n = 46 per group in the final analyses. Mitochondrial staining was performed using n = 23 individual replicates per treatment condition and was repeated across two independent experiments with n = 46 per group in the final analyses using the average of three measurements per experiment. Images in “d” of representative individual myotubes were taken using the 20x objective with red line indicating 150 μm. Relationship between peak mitochondrial metabolism and mitochondrial content was analyzed using linear regression. Metabolic calculations were performed as follows: Basal Respiration = Measurement #3 – Measurement #12; Peak Respiration = Measurement #7 – Measurement #12; Proton Leak = Measurement #average of 4–6 – Measurement #12; Spare Respiratory Capacity = Measurement #7 – Measurement #3; ATP-Linked Respiration = Measurement #3 – Measurement #4–6; Non-Mitochondrial Respiration = Measurement #12. Other Abbreviations: Oligo: oligomycin; FCCP: carbonyl cyanide p-[trifluoromethoxy]-phenyl-hydrazone; and Rot: rotenone.

Figure 6: GW501516 alters lipid metabolism. (a) Representative immunohistochemistry for Glut4 expression (Figure 6(a)). Despite a lack of change at the mRNA level, PGC-1α was significantly increased at the protein level, while protein expression of other related factors remained unaltered (Figure 6(b)). Next, we assessed if GW treatment altered indicators of lipid metabolism. GW treatment had no effect on Ppara or Ppard mRNA expression (Figure 6(c)). Similarly, there were no changes in protein expression of markers of lipid metabolism, including PPARβ/δ, CPT1, ACAD9, and UCP1/2/3 (Figure 6(d)). Next, we assessed the effect of GW on glycolytic metabolism. In-line with the observation that PPARβ/δ agonism increases metabolism, we observed significantly increased basal and peak glycolytic metabolism in GW-treated cells (Figures 7(a), 7(b), and 7(c)). Surprisingly, this increase in basal glycolytic function occurred despite significant reductions in Ldhα and Ldhβ (but not Pdh or Glut4) expression (Figure 7(d)). Collectively, simultaneously increased basal glycolytic and mitochondrial metabolism suggests increased basal metabolism. Similarly, simultaneously increased peak glycolytic and mitochondrial metabolism suggests an overall increase in total metabolic capacity. Importantly, these changes were observed both with and without normalization to nuclei content, which did not differ between groups within the metabolic experiments (Figure 3). Interestingly, despite increased cell metabolism, GW-treated cells displayed subtly but significantly increased lipid content (Figure 8(a)); however, GW treatment reduced Srebp expression at 3 hours (Figure 8(b)). At the protein level, SREBP was reduced following 24 hours of GW treatment, albeit not significantly (p = 0.06, Figure 8(c)). Together, these findings confirm the ability of GW to enhance cell metabolism.

3.2 GW Reduces BCAA Media Content Independent of BCAA Catabolic Enzyme Expression. Because we observed
increased PGC-1α content, which is known to regulate amino acid catabolic enzyme expression [16, 19], we next measured the effect of GW on BCAA content of media following treatment with either control (DMSO) or GW for 24 hours. Consistent with our hypothesis, GW treatment reduced the absolute concentration of each individual BCAA, with significant reductions in valine (Figure 9(a)). Additionally, after normalizing groups to experimental control averages, GW treatment resulted in significant reductions (reduced by roughly 5–6%) in each of the individual BCAA versus control cells (Figure 9(b)). Given we observed significant reductions in the BCAA media content of GW-treated cells, we investigated the effect of GW on BCAA catabolic enzyme expression. To our surprise, GW at 1 μM for either 3, 6, or 24 hours did not alter the mRNA expression of Bckdha, Bcat2, or the valine-specific catabolic gene 3-hydroxyisobutyrate dehydrogenase (Hibadhi) (Figure 9(c)). Similarly, no changes were observed in the protein expression of LAT1 (the predominant BCAA transporter), BCKDHa, pBCKDHA, or BCAT2 after 24-hour treatment (Figure 9(d)). Taken together, these findings suggest heightened BCAA uptake (and possibly metabolism) may occur without substantial changes in the protein levels of related cell machinery.

3.3. Effect of GW with and without Insulin Resistance on BCAA Catabolic Enzyme Expression and BCAA Media Content. Lastly, we reassessed the effect of GW on indicators of BCAA metabolism both with and without insulin resistance, both with and without the PPARβ/δ inhibitor GSK3787. As expected, insulin resistance was confirmed by reduced pAkt activation following insulin stimulation (Figure 10(a)), though no main effect of GW was observed.
Next, we assessed BCAA catabolic enzyme expression and again found no effect of GW on BCAT2, BCKDHa, or pBCKDHa expression (Figures 10(b), 10(c), and 10(d)), though we did observe a main effect of insulin resistance for reduced BCAT2 expression (Figure 10(b)). Lastly, we assessed the effect of each treatment condition on individual and cumulative media BCAA content and found a significant effect of GW for isoleucine when comparing GW to...
true control, but not leucine, valine, or cumulative media BCAA content (Figure 10(e)). Interestingly, upon further normalization to independent experiments, significant effects of GW were observed for isoleucine, valine, and cumulative BCAA when comparing GW to true control, which was not observed for leucine (Figure 10(f)). Also interesting was the observation that significant simple main effects of GW were only observed when comparing true control and GW-only treated cells (which was also observed in previous experiments, see Figure 9), while GW had no significant effect on BCAA metabolites in any of the other paired comparisons (Figure 10(f)).

4. Discussion

PPARβ/δ regulates several important aspects of muscle energetics and mitochondrial content. Through interactions with PGC-1α, PPARβ/δ activation can enhance mitochondrial content and lipid oxidation. Thus, given the several observations that show PPARβ/δ can upregulate PGC-1α, and the observations that PGC-1α (along with PPARs) can regulate BCAA catabolic gene expression, we assessed whether PPARβ/δ agonism could upregulate BCAA disposal and/or catabolic machinery with GW, a commonly used PPARβ/δ agonist [1, 25, 27–29, 42, 44, 45, 50]. In line with our original hypothesis, we observed consistently lower BCAA content in the media of GW-treated cells versus control. These findings suggest heightened BCAA uptake (and possibly metabolism) may occur without substantial changes in the protein levels of related catabolic machinery. During follow-up experiments with both insulin sensitive and insulin resistant cells both with and without the presence of a PPARβ/δ inhibitor, we again found GW lowered BCAA media content in insulin sensitive cells that did not receive
the inhibitor (again, independent of change in BCAT2 or BCKDHa), but not in other experimental groups. The implications of these findings are unclear as altered media amino acid content could suggest improved metabolism or simply increased uptake (which were not assessed in this report). Thus, to clarify the true effect of GW on BCAA metabolism, BCAA tracer experiments may be required. That being said, given extracellular BCAA accumulation is the primary correlate of BCAA versus insulin resistance, extracellular BCAA content is an ideal measurement in this context. Additionally, while we did not observe altered BCAA media content during insulin resistance, previous experiments have verified this effect (though in the previous experiments, cells received twice the duration of insulin resistance [41]). Thus, BCAA accumulation in this model of insulin resistance may only occur after more chronic exposure to hyperinsulinemic conditions, which is another variable worthy of further exploration.

Beyond BCAA media content, we also assessed the effect of GW on BCAA catabolic machinery. However, contrary to our hypothesis (and despite lower BCAA media content), PPARβ/δ agonism with GW did not alter BCAA catabolic enzyme expression at the mRNA or protein level, nor did

**Figure 9: Effect of GW501516 on BCAA transport and catabolic enzymes.** (a and b) Effect of treatment with GW501516 (GW) at 1 μM for 24 hours on (a) absolute media BCAA content or (b) control mean-normalized (within each experiment) media BCAA content following 24-hour treatment. (c) Effect of GW at 1 μM for up to 24 hours on myotube mRNA expression of branched-chain aminotransferase 2 (Bcat2), branched-chain alpha-keto acid dehydrogenase (Bkdha), and 3-hydroxyisobutyrate dehydrogenase (Hibadh). (d) Effect of GW at 1 μM for 24 hours on myotube protein expression of large amino acid transporter 1 (LAT1), pBCKDHa (normalized to total BCKDHa), BCKDHa, and BCAT2. Notes: * indicates $p \leq 0.05$ between groups. Time course gene expression was analyzed using one-way ANOVA with Dunnett’s correction for multiple comparisons. Target gene expression was normalized to tata binding protein (Tbp) using three replicates per group across two independent experiments with $n = 5 – 6$ for the final analysis. Protein expression and BCAA media content were analyzed using student’s $t$-test. Western blots were performed using three replicates per group across two independent experiments with $n = 6$ for the final analysis with each analyte measured in triplicate.
Figure 10: Continued.
it alter the activity (indicated by phosphorylation status) of the rate-limiting enzyme complex (BCKD). We found this surprising because we observed increased PGC-1α following GW treatment, and several previous experiments have shown ectopic PGC-1α over-expression in C2C12 cells consistently upregulated expression of amino acid metabolism [16, 19], which appears to translate in vivo [30]. That being said, the metabolism of BCAA is also dependent on substrate availability (including BCAA, NADH, acyl-CoA, and other) in addition to enzyme abundance and phosphorylation state of the BCKDH complex (details of which are reviewed in detail elsewhere [51]). For example, BT2, an inhibitor of BCKDK, markedly reduced BCKDH complex phosphorylation in various tissues yet only enhanced BCAA metabolism in skeletal muscle [52]. Our findings demonstrate GW-only treated cells exhibited increased BCAA utilization independent of change in BCKDHa phosphorylation, which supports the observation that phosphorylation state of the BCKDH complex is only one of several regulatory mechanisms. Moreover, there are certainly conceivable differences that occur during PGC-1α over-expression experiments, which undoubtedly lead to more pronounced activation of several metabolic pathways. And importantly, Kleiner et al. also demonstrated that PPARβ/δ agonism via GW is dependent on PGC-1α abundance [42]. Thus, while we observed significant increases in PGC-1α protein content, it could be that the increase was too subtle to elicit some of the anticipated effects of the measured molecular targets. Moreover, several related and alternative targets were not explored by the current report (such as LAT2). Such targets may be relevant as previous experiments have demonstrated a dispensable nature of LAT1, which is compensated for by other transports [53–55]. This example of LAT1 dispensability has been shown in gastrocnemius of LAT1-knockout mice that exhibit increased LAT2 mRNA expression (Scl7a8) and do not display altered intra-gastrocnemius leucine content following a fed state (and display elevated leucine content under a fasting state) [55]. Our findings seem to agree with other experiments showing LAT1 abundance is not dependent on cell culture media leucine content in myocytes [56], nor dependent on dietary protein within skeletal muscle [57]. Together, our study provides a first level of evidence suggesting PPARβ/δ agonism with GW may upregulate BCAA metabolism.

Another important finding worthy of comment was our observation of increased PGC-1α protein content that occurred independent of enhanced Pparγc1a expression, which is in-line with several other observations [58–61]. Specifically, Luquet et al. showed that despite upregulated indicators of lipid oxidation, muscle-specific PPARβ/δ over-expression did not alter mRNA expression of Pparγc1a, Tfam, or Fat [61]. Similarly, muscle-specific PPARβ/δ over-expression performed by Wang et al. demonstrated increased mitochondrial biogenesis independent of changes in Pparγc1a expression [60]. Kleiner et al. showed that PPARβ/δ agonism via GW could enhance primary mouse myotube lipid metabolism, which occurred independent of changes in mRNA expression of regulators of mitochondrial biogenesis and content (Pparγc1a, Pparγc1b, Esrra, Cytc, Atp5a1, and Id3a) and mitochondrial respiratory protein content [42]. The same report also verified increased indicators of lipid oxidation but not mitochondrial biogenesis in the skeletal muscle of both lean and ob/ob mice given GW [42]. Interestingly, the same study also demonstrated the suppression of PGC-1α abolished the increased lipid oxidation capacity induced by GW [42]. Other reports using mice with myocardial infarction have also shown GW increases markers of lipid oxidation independent of increased Pparγc1a expression [27]. Since these original observations, it has since been established PPARβ/δ can elevate muscle PGC-1α protein content independent of Pparγc1a expression [58], which appears to be mediated by PPARβ/δ suppression of PGC-1α protein ubiquitination and degradation [59].

PPARβ/δ activation via GW has also been shown by some experiments to upregulate PGC-1α expression and mitochondrial biogenesis in skeletal muscle both in vitro...
and in vivo [1]. Another report that used a similar model and treatment protocol as the present report showed C2C12 myoblasts treated for 24 hours with 1 μM GW displayed increased PGC-1α promoter activity and mRNA expression [25]. Similarly, C2C12 myotubes treated with GW for 24 hours displayed increased PGC-1α mRNA [26]. Moreover, treatment with GW and BM649 (a selective RXR agonist) induced PGC-1α expression in C2C12 myocytes [8]. It is unclear why this disparity in expression exists between reports using GW as a PPARβ/δ agonist; however, it has been shown during experiments in C2C12 cells using GW as a PPARβ/δ agonist that PPAR response element (PPRE) activation is likely dependent on several factors, including PGC-1α abundance and RXR activation [44].

Similar suggestions have been made by other researchers who showed no effect of GW on indicators of mitochondrial biogenesis within a cell culture model of skeletal muscle or in mouse in vivo experiments [42].

Other reports have also examined the effect of GW on muscle metabolism. For example, one similar report treated C2C12 cells with 1 μM concentration for 24 hours as performed in the presented experiments. This report showed no effect of GW on basal or peak mitochondrial respiration but showed increased uncoupling with the addition of GW. The report also found elevated levels of Cpt1 expression, which we did not observe during our experiments at the protein level. Additionally, our report identified a significant increase in basal and peak mitochondrial function as well as mitochondrial content in GW-treated cells. However, an important difference between the two reports was the co-treatment with palmitate performed by Tumova et al., which investigated the involvement of PPARβ/δ in suppressing the negative effects of palmitate on myocyte survival. Thus, perhaps the effect of GW on expression profiles is dependent on the availability of other lipids. Moreover, elevated muscle-specific PGC-1α overexpression has also been linked with increased lipid content and lipogenic signaling in skeletal muscle of sedentary and exercised mice [62, 63]. This too appears to occur in a way proportional to other signaling molecules (such as SREBP1c and LXR/RXR) [62]. Collectively, induction of PGC-1α and activation of PPARβ/δ may promote increased cellular lipid content (as seen in our report) to support increased oxidative metabolism.

It is also worth highlighting some additional study limitations and considerations. First, although we used a similar treatment protocol to several other experiments [25, 26, 28, 31], we cannot exclude the possibility that our treatment conditions with GW were not optimized to yield comparable results with studies demonstrating increased Ppargc1a (optimization that may be required to elicit an observable effect on BCAA catabolic capacity, as well as that of other pathways such as lipid metabolism). However, we did observe increased PGC-1α protein content, and thus we suspect that had PPARβ/δ agonism via GW been sufficient to activate BCAA catabolic machinery, we would have observed some change in the measured indicators. However, it is also conceivable that GW might elicit a different response in the presence of supplemental RXR agonism, various lipids, or in the treatment of diseased cells (versus the otherwise healthy cells used in our experiments). Moreover, while we assessed BCAA concentration in the media (as a surrogate for circulating BCAA blood levels) following treatment and showed differences between groups indicating GW enhances BCAA disposal, we did not vary BCAA levels to determine if GW’s effect on BCAA metabolism is dependent on BCAA abundance. Thus, these data should be interpreted with these limitations in mind. Despite these limitations, we feel our report provides an informative overview of the effect of PPARβ/δ agonism on myotube metabolism and regulation of BCAA metabolism, which collectively suggest PPARβ/δ agonism via GW increases BCAA disposal in a manner independent of alterations in BCAA catabolic machinery abundance.

**Abbreviations**

- **AMPK-5ˈ**: AMP-activated protein kinase
- **Atp5b**: ATP synthase (mRNA transcripts from Atp5b gene)
- **BCAA**: Branched-chain amino acid
- **Bcat2**: Branched-chain amino acid transaminase 2 (mRNA)
- **BCAT2**: Branched-chain amino acid transaminase 2 (protein)
- **Bckdh**: Branched-chain alpha-keto acid dehydrogenase (mRNA)
- **BCKD** H: Branched-chain alpha-keto acid dehydrogenase (protein)
- **BCKDK**: Branched-chain alpha-keto acid dehydrogenase kinase (protein)
- **Cox5a**: Cytochrome c oxidase (mRNA transcripts from Cox5a)
- **Cpt1**: Carnitine palmitoyl transferase 1 (mRNA)
- **Cpt1b**: Carnitine palmitoyl transferase 1 b (protein)
- **Cs**: Citrate synthase (mRNA)
- **CS**: Citrate synthase (protein)
- **ECAR**: Extracellular acidification rate
- **ERα**: Estrogen-related receptor alpha (protein)
- **Esra**: Estrogen-related receptor alpha (mRNA)
- **FCCP**: Carbonyl cyanide p-[trifluoromethoxy]-phenylhydrazone
- **GLUT4**: Glucose transporter 4 (protein)
- **GW**: GW501516
- **Hibadh**: 3-hydroxyisobutyrate dehydrogenase (mRNA)
- **Slc7a5**: Large amino acid transporter 1 (mRNA)
- **LAT1**: Large amino acid transporter 1 (protein)
- **Slc7a8**: Large amino acid transporter 2 (mRNA)
- **LAT2**: Large amino acid transporter 2 (protein)
- **Ldhα**: Lactate dehydrogenase A (mRNA)
- **Ldhβ**: Lactate dehydrogenase B (mRNA)
- **mtDNA**: Mitochondrial DNA
- **Nrf1**: Nuclear respiratory factor 1 (mRNA)
- **NRF1**: Nuclear respiratory factor 1 (protein)
- **OCR**: Oxygen consumption rate
- **PGC-1α**: Peroxisome proliferator-activated receptor gamma coactivator 1-alpha (protein)
- **Ppargc1a**: Peroxisome proliferator-activated receptor gamma coactivator 1-alpha (mRNA)
**Data Availability**

The data that support the findings of this study are available from the corresponding author upon reasonable request.

**Conflicts of Interest**

The authors declare that they have no conflicts of interest.

**Authors’ Contributions**

CNR, JSH, RMW, TCM, and AJW conducted experiments and assisted with manuscript preparation. RAV conceived the study, conducted and oversaw experiments, performed all statistical analyses, and oversaw manuscript preparation. All authors have read and approved the final manuscript.

**Acknowledgments**

Support for this work was provided by the Department of Exercise Science within the Congdon School of Health Sciences. Additional support was provided by the High Point University Undergraduate Research and Creative Works Small Project Support Grant (F-21-02), and by the Summer Undergraduate Research Fellowship (SURF) within the Congdon School of Health Sciences. We would like also to thank the Department of Physical Therapy (Congdon School of Health Sciences) for the use of shared lab space and equipment. RMW was supported by the HPU Natural Science Fellows Program. Instrumentation support was provided by the Shimadzu Partnership for Academics, Research and Quality of Life (SPARQ) Program.

**References**


[57] M. Mazzulla, N. Hodson, M. Lees et al., “LAT1 and SNAT2 protein expression and membrane localization of LAT1 are not acutely altered by dietary amino acids or resistance exercise nor positively associated with leucine or phenylalanine incorporation in human skeletal muscle,” *Nutrients*, vol. 13, no. 11, p. 3906, 2021.


